Core Viewpoint - The preliminary results of CT0596, an allogeneic CAR-T cell therapy targeting BCMA, were reported at the 67th American Society of Hematology (ASH) Annual Meeting, indicating promising safety and efficacy signals in patients with relapsed/refractory multiple myeloma [1][2]. Group 1 - CT0596 is developed based on the company's proprietary THANK-u Plus™ platform and is currently undergoing investigator-initiated clinical trials for relapsed/refractory multiple myeloma (R/R MM) and plasma cell leukemia (PCL) [2]. - Initial results show good safety and encouraging efficacy signals, with CAR-T cell expansion observed across all predefined dose groups [2]. - The company plans to explore CT0596 in other plasma cell tumors and autoimmune diseases driven by autoreactive plasma cells [2]. Group 2 - The IND application for CT0596 is expected to be submitted in the second half of 2025 [2].

香港交易及結算所有限公司、香港聯合交易所有限公司及香港中央結算有限公司對本公告的內 容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 CARsgen Therapeutics Holdings Limited 科濟藥業控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2171） 自願公告 於2025年ASH年會上呈列的CT0596的研究成果更新 本公告由科濟藥業控股有限公司（「本公司」，連同其附屬公司及併表聯屬實體統 稱「本集團」或「科濟藥業」）自願作出，以告知本公司股東及潛在投資者本集團最 新業務更新。 本公司董事會（「董事會」）宣佈，CT0596（一種靶向BCMA的同種異體CAR-T細胞 候選產品）的初步結果已在第67屆美國血液學會（「ASH」）年會上進行報告。更多 詳情請參見本公司官網 www.carsgen.com 。 CT0596 IIT初步研究結果已於美國東部時間2025年12月6日下午5:30－下午 7:30，在第67屆ASH年會上進行壁報展示，標題為「CT0596（一種靶向BCMA 的同 ...

Group 1 - Netflix announced an agreement to acquire Warner Bros. Discovery for an enterprise value of approximately $82.7 billion, focusing on its film studios and HBO Max streaming assets, including top IPs like Harry Potter and Game of Thrones, aiming to build a "super content" empire, with the deal expected to face strict antitrust scrutiny [3] - OpenAI plans to respond to Google's Gemini 3 with the upcoming GPT-5.2, which is now expected to launch on December 9, ahead of its original schedule [3] - SpaceX is reportedly seeking an $800 billion valuation through a share sale, although Elon Musk denied the accuracy of this report, stating that revenue from NASA is expected to account for no more than 5% of the company's income by 2026 [4] Group 2 - X, the social platform owned by Musk, was fined €120 million under the EU's Digital Services Act for allegedly violating content moderation regulations [4] - Microsoft is in talks with Broadcom to design future custom chips, potentially shifting from its current supplier Marvell [4] Group 3 - Xingqi Eye Care has multiple products included in the National Medical Insurance Directory, with a notable product priced at 1.78 yuan per piece, expected to positively impact long-term operations [6] - Kexin Pharmaceutical's CAR-T drug has entered the commercial insurance innovative drug directory, drawing market attention [6] - Wuliangye will adjust the price of its eighth-generation product starting next year, offering a discount of 119 yuan per bottle from a base price of 1019 yuan [7] Group 4 - Huawei's CEO emphasized the importance of AI research while focusing on the application of large models and big data in agriculture and technology over the next 3-5 years [6] - BYD's chairman noted a decline in domestic sales due to technological lag and user demand issues, indicating the need for significant technological breakthroughs [7] - Baidu Kunlun Chip plans to file for an IPO in Hong Kong as early as Q1 next year, with a recent valuation of 21 billion yuan [7] Group 5 - Samsung Electronics achieved a key breakthrough in 4nm process technology, improving yield rates to 60-70%, which is expected to enhance its competitiveness in advanced manufacturing [12] - SK Hynix announced plans to localize EUV photoresist to reduce dependence on Japanese suppliers [12]

Core Insights - The introduction of five CAR-T cell therapies into the Commercial Health Insurance Innovative Drug Directory marks a significant breakthrough for these high-cost treatments, which previously struggled to gain access to national insurance negotiations [1][3][4] Group 1: Benefits of Inclusion - The five CAR-T therapies included are aimed at treating various blood cancers, providing hope for potential cures in conditions like large B-cell lymphoma, multiple myeloma, and acute lymphoblastic leukemia [3] - The inclusion of these therapies in the directory is seen as a milestone for improving patient accessibility to innovative drugs in China [4][5] - The pricing of these therapies varies, with the lowest being 999,000 yuan (approximately 99.9 million) for the product from 合源生物, while the highest is 1,290,000 yuan (approximately 129 million) for the product from 药明巨诺 [1] Group 2: Market Dynamics and Cost Considerations - The high production costs of CAR-T therapies, particularly due to the expensive lentiviral vectors sourced from foreign suppliers, have historically limited their pricing and accessibility [3] - Some companies have reported that their CAR-T products will see price reductions of at least 15% upon inclusion in the directory, which is expected to be more favorable than local health insurance programs [5] Group 3: Implementation Challenges - The successful inclusion of CAR-T therapies in the directory raises questions about the practical implementation and accessibility in hospitals, as the directory's effectiveness relies on its adoption at the hospital level [6][7] - Policies such as the "three exclusions" from basic medical insurance and centralized procurement monitoring are designed to alleviate concerns from hospitals and physicians regarding cost assessments, potentially facilitating the entry of these drugs into hospitals [6][7] - There are ongoing discussions about further coordination between the National Medical Insurance Administration and health authorities to ensure that the performance assessments of hospitals do not hinder the adoption of these innovative therapies [7]

科济药业-B（02171）公布，2025年12月1日耗资约296.395万港元回购17.35万股股份。 来源：新浪港股 ...

格隆汇12月1日丨科济药业-B(02171.HK)公告，12月1日耗资296.4万港元回购17.4万股。 ...

智通财经APP讯，科济药业-B(02171)公布，2025年12月1日耗资约296.395万港元回购17.35万股股份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 科濟藥業控股有限公司 呈交日期： 2025年12月1日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 第 2 頁 共 7 頁 v 1.3.0 FF305 FF305 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 科濟藥業控股有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02171 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 200,000,000,000 | USD | 0.00000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 200,000,000,000 | USD | 0.00000025 | USD | | 50,000 | 本月底法定/註冊股本總額： USD ...

智通财经APP获悉，香港联交所最新数据显示，11月24日，非执行董事郭华清增持科济药业(02171)3万 股，每股作价16.39港元，总金额为49.17万港元。增持后最新持股数目约为2.18亿股，持股比例为 37.75%。 ...